Mass spectrometry quantification of clusterin in the human brain
Open Access
- 20 August 2012
- journal article
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 7 (1) , 41
Abstract
Background: The multifunctional glycoprotein clusterin has been associated with late-onset Alzheimer’s disease (AD). Further investigation to define the role of clusterin in AD phenotypes would be aided by the development of techniques to quantify level, potential post-translational modifications, and isoforms of clusterin. We have developed a quantitative technique based on multiple reaction monitoring (MRM) mass spectrometry to measure clusterin in human postmortem brain tissues. Results: A stable isotope-labeled concatenated peptide (QconCAT) bearing selected peptides from clusterin was expressed with an in vitro translation system and purified. This clusterin QconCAT was validated for use as an internal standard for clusterin quantification using MRM mass spectrometry. Measurements were performed on the human postmortem frontal and temporal cortex from control and severe AD cases. During brain tissues processing, 1% SDS was used in the homogenization buffer to preserve potential post-translational modifications of clusterin. However, MRM quantifications in the brain did not suggest phosphorylation of Thr393, Ser394, and Ser396 residues reported for clusterin in serum. MRM quantifications in the frontal cortex demonstrated significantly higher (P < 0.01) level of clusterin in severe AD group (39.1 ± 9.1 pmol/mg tissue protein) in comparison to control group (25.4 ± 4.4 pmol/mg tissue protein). In the temporal cortex, the clusterin levels were not significantly different, 29.0 ± 7.9 pmol/mg tissue protein and 28.0 ± 8.4 pmol/mg tissue protein in control and severe AD groups, respectively. Conclusions: The proposed protocol is a universal quantitative technique to assess expression level of clusterin. It is expected that application of this protocol to quantification of various clusterin isoforms and potential post-translational modifications will be helpful in addressing the role of clusterin in AD.Keywords
This publication has 20 references indexed in Scilit:
- Quantotypic Properties of QconCAT Peptides Targeting Bovine Host Response toStreptococcus uberisJournal of Proteome Research, 2012
- Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer DiseaseArchives of General Psychiatry, 2010
- Optimizing the Conditions of a Multiple Reaction Monitoring Assay for Membrane Proteins: Quantification of Cytochrome P450 11A1 and Adrenodoxin Reductase in Bovine Adrenal Cortex and RetinaAnalytical Chemistry, 2010
- An Initial Characterization of the Serum PhosphoproteomeJournal of Proteome Research, 2009
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Comparative Evaluation of Current Peptide Production Platforms Used in Absolute Quantification in ProteomicsMolecular & Cellular Proteomics, 2008
- Stoichiometry and Absolute Quantification of Proteins with Mass Spectrometry Using Fluorescent and Isotope-labeled Concatenated Peptide StandardsMolecular & Cellular Proteomics, 2008
- Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated formsNeurochemistry International, 2006
- Clusterin (Apolipoprotein J) Protein Levels Are Increased in Hippocampus and in Frontal Cortex in Alzheimer's DiseaseExperimental Neurology, 1998
- Brain Expression of Apolipoproteins E, J, and A‐I in Alzheimer's DiseaseJournal of Neurochemistry, 1996